Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | MMP1 | P03956 | 7/20 | 0.69 |
| ▸ | MMP2 | P08253 | 7/20 | 0.69 |
| ▸ | MMP9 | P14780 | 7/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.62 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.62 |
| ▸ | MAOA | P21397 | 2/20 | 0.62 |
| ▸ | MAOB | P27338 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL729590 | 1.00 | EGFR (1.00) | EGFRTP53MAPTSMN1; SMN2MMP1 | |
| SCHEMBL5764816 | 1.00 | EGFR (1.00) | EGFRTP53MAPTSMN1; SMN2MMP1 | |
| SCHEMBL10492426 | 0.88 | MMP1 (0.80) | EGFRMAPTMMP1MMP2MMP9 | |
| SCHEMBL10492424 | 0.88 | MMP1 (0.80) | EGFRMAPTMMP1MMP2MMP9 | |
| SCHEMBL3150080 | 0.86 | EGFR (0.76) | EGFRTP53MAPTSMN1; SMN2MMP1 | |
| SCHEMBL3150070 | 0.86 | EGFR (0.76) | EGFRTP53MAPTSMN1; SMN2MMP1 | |
| SCHEMBL11859673 | 0.85 | EGFR (0.74) | EGFRTP53MAPTSMN1; SMN2MMP1 | |
| SCHEMBL11859691 | 0.85 | EGFR (0.74) | EGFRTP53MAPTSMN1; SMN2MMP1 | |
| SCHEMBL20660618 | 0.82 | EGFR (0.75) | EGFRTP53MAPTSMN1; SMN2MMP1 | |
| SCHEMBL20660616 | 0.82 | EGFR (0.75) | EGFRTP53MAPTSMN1; SMN2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10807997-B2 | Methods for making quinolinyldiamines | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200071344-A1 | METHODS FOR MAKING QUINOLINYLDIAMINES | EXXONMOBIL CHEMICAL PATENTS INC. | 2020-03-05 | — | — | US | disclosed |
| WO-2020046794-A1 | METHODS FOR MAKING QUINOLINYLDIAMINES | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2020-03-05 | — | — | WO | disclosed |
| US-9394297-B2 | Amides as pim inhibitors | AMGEN INC. (US) | 2016-07-19 | — | — | US | disclosed |
| CN-103214482-B | Imidazo [1,2-a] pyridine compounds as receptor tyrosine kinase inhibitors | 阵列生物制药公司 | 2016-06-29 | — | — | CN | disclosed |
| US-20150329538-A1 | AMIDES AS PIM INHIBITORS | AMGEN INC. (US) | 2015-11-19 | — | — | US | disclosed |
| WO-2013130660-A1 | AMIDES AS PIM INHIBITORS | AMGEN INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| EP-2137184-B1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2013-05-08 | — | — | EP | disclosed |
| US-8138181-B2 | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-03-20 | — | — | US | disclosed |
| EP-2136807-B1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LTD (GB) | 2010-11-03 | — | — | EP | disclosed |
| EP-1980251-A1 | Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis | GLAXO GROUP LIMITED (GB) | 2008-10-15 | — | — | EP | disclosed |
| WO-2008121687-A2 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20080221110-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-11 | — | — | US | disclosed |
| EP-1954697-A2 | PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007081597-A2 | PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-07-19 | — | — | WO | disclosed |
| US-7019147-B1 | Benzimidazole derivatives useful as antiproliferative agents | PFIZER INC. (US) | 2006-03-28 | — | — | US | disclosed |
| EP-1235825-B1 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | PFIZER PROD INC (US) | 2006-01-25 | — | — | EP | disclosed |
| CN-1402721-A | Novel benzimidazole derivatives as antiproliferative agents | PFIZER PROD INC (US) | 2003-03-12 | — | — | CN | disclosed |
| EP-1235825-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | Pfizer Products Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001040217-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | PFIZER PRODUCTS INC. (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221110-A1 | Compounds | NRDC, NISCH, MRPL21 | EGFR 891/4885TP53 1941/4885MAPT 1138/4885 |
| US-20150329538-A1 | AMIDES AS PIM INHIBITORS | PIM1, PIM3, PIM2 | EGFR 367/4885TP53 129/4885MAPT 3261/4885 |
| US-20200071344-A1 | METHODS FOR MAKING QUINOLINYLDIAMINES | NNMT, PNMT, HNMT | EGFR 3801/4885TP53 2100/4885MAPT 1630/4885 |
| US-10807997-B2 | Methods for making quinolinyldiamines | NNMT, PNMT, HNMT | EGFR 3801/4885TP53 2100/4885MAPT 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.